What is Verve Therapeutics Inc (VERV)?

Verve Therapeutics Inc（VERV）股票分析

$11.130

+0.030 (+0.27%)收盘时

Loading chart…

High: 11.250
Open: 11.140
VWAP: 11.16
Vol: 10.31M
Mkt Cap: 399.68M
Low: 11.100
Amount: 115.02M
EV/EBITDA, TTM: -0.21

Verve Therapeutics, Inc. is a clinical-stage company. The Company is focused on developing a new class of genetic medicines for cardiovascular disease with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The Company’s lead programs include VERVE-102, VERVE-201, and VERVE-301, which target the three cholesterol drivers of atherosclerosis: LDL-C, remnant cholesterol, and Lp(a). VERVE-102 is designed to permanently turn off the PCSK9 gene in the liver and is being developed initially for heterozygous familial hypercholesterolemia (HeFH) and ultimately to treat patients with established atherosclerotic cardiovascular disease (ASCVD) who continue to be impacted by high LDL-C levels. VERVE- 201 is designed to permanently turn off the ANGPTL3 gene in the liver and is initially being developed for refractory hypercholesterolemia. VERVE-301 is designed to permanently turn off the LPA gene to reduce Lp(a) levels.

www.vervetx.com

估值指标

The current forward P/E ratio for Verve Therapeutics Inc (VERV) is -2.17, compared to its 5-year average forward P/E of -6.26.

Forward P/E

Fair

5Y Average P/E

-6.26

Current P/E

-2.17

高估

-0.87

低估

-11.65

Forward EV/EBITDA

Fair

5Y Average EV/EBITDA

-3.89

Current EV/EBITDA

-0.21

高估

1.06

低估

-8.84

Forward P/S

Fair

5Y Average P/S

325.56

Current P/S

39.85

高估

771.90

低估

-120.79

Alphio AI Price Scenarios for VERV

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

Bull

Bull · 25%VERV

$13.80

情景价格

Base

Base · 50%VERV

$12.12

情景价格

Bear

Bear · 25%VERV

$9.10

情景价格

事件时间线

2025-07-25 (ET)